CNS Pharmaceuticals Inc (OQ:CNSP)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2100 West Loop S Ste 900
HOUSTON TX 77027-3522
Tel: N/A
Website: N/A
IR: N/A
<
Key People
N/A    
Business Overview
CNS Pharmaceuticals Inc. is a preclinical stage pharmaceutical company. The Company is focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors. The Company is focused on developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity. It results in the inhibition of DNA replication and repair, and Ribonucleic acid (RNA) and protein synthesis.
Financial Overview
For the nine months ended 30 September 2019, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 78% to $1.3M. Higher net loss reflects Research and development increase from $21K to $370K (expense), Selling/General/Admin Expense increase of 44% to $939K (expense), Interest expense increase of 25% to $23K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.05 to -$0.10.
Employees: 1 as of Mar 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $70.90M as of Sep 30, 2019
Annual revenue (TTM): $0.00M as of Sep 30, 2019
EBITDA (TTM): -$1.52M as of Sep 30, 2019
Net annual income (TTM): -$7.98M as of Sep 30, 2019
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 16,450,234 as of Dec 20, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization